

## DAFTAR PUSTAKA

- American Thoracic Society, 2005, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med*, **171**:388–416.
- American Thoracic Society. 1996, Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies [consensus statement]. *Am J Respir Crit Care Med*; **153**:1711–1725.
- Andes D, Anon J, Jacobs MR, Craig WA. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. *Clin Lab Med* 2004; **24**:477–502.
- Arancibia F, Bauer TT, Ewig S, et al. 2002. Community-acquired pneumonia due to gram-negative bacteria and *Pseudomonas aeruginosa*: incidence, risk, and prognosis. *Arch Intern Med*. **162**:1849-1858.
- Arias C.A, Murray BE., 2009. Antibiotic-resistant bugs in the 21st century Vaclinical super-challenge. *N Engl J Med*, **360**:439-443.
- Attridge RT, Frei CR, Restrepo MI, Lawson KA, Ryan L, Pugh MJ, et al., 2011. Guideline-concordant therapy and outcomes in healthcare- associated pneumonia. *Eur Respir J*, **38**:878-887
- Bauer, L.A., 2008. *Applied Clinical Farmakokinetics*, 2nd ed. The McGraw-Hill Medical .
- Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., dkk., 2009. Bad bugs no drugs. *An update from the Infectious Diseases Society of America Clin Infect Dis*, **48**:1-12.
- Brandon J. W., Benjamin S., Dangerfield B., Jabraan S., Pasha C., Neera A.D., et al., 2012. Guideline-concordant antibiotic therapy and clinical outcomes in healthcare-associated pneumonia. *Respir Med*, **106**: 1606-161.
- Brunton, L.L., Lazo, J.S., Parker, K.L., Buxton, Iain, L.O., dan Blumenthal, D.K., 2006. *Goodman and Gillman's The Pharmacological Basis of Therapeutics*, 11th ed. The McGraw-Hill Companies, Inc, USA.
- Calbo, E. and Garau, J., 2005. Application of Pharmacokinetics and Pharmacodynamics of Antimicrobial Therapy of Community-Acquired Respiratory Tract Infections. *Respiration*, **72**: 561–571.

- Carpenter, C.F. and Chambers, H.F., 2004. Daptomycin: Another Novel Agent for Treating Infections Due to Drug-Resistant Gram-Positive Pathogens. *Clin Inf Dis*, **38**: 994–1000.
- Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, *et al.* 2003. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. *JAMA*, **290**: 2588–2598.
- Craig WA. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of  $\beta$ -lactams, glycopeptides, and linezolid. *Infect Dis Clin North Am*, **17**: 479–501.
- Cunha B.A., 2001. Nosocomial Pneumonia : Diagnostic and therapeutic considerations. *The Med Clin of North America*, **20**: 79 – 114.
- Cynthia, A.B. dan Steven, P.G., 2002. *An Update on Treatment of Community Acquired Pneumonia*. Temple University School of Pharmacy.
- Dahlan, Z., 2009. *Pneumonia Dalam : Buku Ajar Ilmu Penyakit Dalam Jilid III*. Interna Publishing, Jakarta Pusat.
- Dahlan, Z., 2012. *Kompendium Tatalaksana Respirologi Respirasi Kritis*. PERPARI, Bandung.
- DeFrances C.J., Lucas C.A., Buie V.C., Golosinskiy A., 2006. National Hospital Discharge Survey. *Natl Health Stat Report*, **2008**: 1-20.
- Dhainaut J.F., Laterre P.F., LaRosa S.P., Levy H., Garber G.E., Heiselman D., *et al.*, 2003. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. *Crit Care Med*, **31**: 2291-2301.
- Drusano G.L., 2004. Antimicrobial Farmakodinamiks: critical interactions of 'bug and drug'. *NatRev Microbiol*, **2**: 289-300.
- Edmunds J., Mykietiuk A., Fernandez S.N., Surez C., Dorca J., Verdaguer R., *et al.* 2007. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. *Archives of Int Med*, **167**: 1393-1399.
- Engleberg, N.C., Dermody, T., dan Dirita, V., 2012. *Schaechter's Mechanisms of Microbial Disease*. Lippincott Williams & Wilkins, North American.
- Falcone M, Venditti M, Shindo Y, Kollef MH, 2011. Healthcare-associated pneumonia: Diagnostic criteria and distinction from community-acquired pneumonia. *Int J Infect Dis*, **15**: 545-550.

- Fei Q.I., Guo X.Z., Dan Y.S., Zhi X.L., Ren T.W., Zhen Y., *et al.* 2015. Healthcare-associated Pneumonia: Clinical Features and Retrospective Analysis Over 10 Years. *Chinese Med J.* **128**:1707-1713.
- Ferrer R., Artigas A., Suarez D., Palencia E., Levy M.M., Arenzana A., *et al.*, 2009. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. *Am J Respir Crit Care Med*, **180**:861-866.
- Fink MP, Snyderman DR, Niederman MS, Leeper KVJ, Johnson RH, Heard SO, *et al.*, Severe Pneumonia Study Group. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, doubleblind trial comparing intravenous ciprofloxacin with imipenem–cilastatin. *Antimicrob Agents Chemother* 2004;**38**:547–557.
- Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, *et al.*, 2002.. Healthcare-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. *Ann Intern Med*,**137**:791–797.
- Gaynes R., 2002. Health-care associated bloodstream infections: a change in thinking. *Ann Intern Med*,**137**:850–851.
- Glover, M.L. dan Reed, M.D., 2008. Lower Respiratory Tract Infection, dalam: *Pharmacotherapy Pathophysiologic Approach*. McGraw Hill Medical Companies, Inc.
- Hakim, L., 2012. *Farmakokinetika Klinik*, Farmasi Klinis. Bursa Ilmu, Yogyakarta.
- Heron M., Hoyert D.L., Murphy S.L., 2009. Deaths: final data for 2006. *Natl Vital Stat Rep*, **57**:1-134.
- Hutt E, Kramer AM., 2002. Evidence-based guidelines for management of nursing home-acquired pneumonia. *J Fam Pract* 2002;**51**:709–716.
- James D.C, Joann K.T., Gillian B.F., Ahsan R.A., Pallavi M, Adam T.H., *et al.* 2011. Epidemiology, Antibiotic Therapy, and Clinical Outcomes in Health Care Associated Pneumonia : A UK Cohort Study. *Clin Infect Dis*, **53**:107–113.
- Jordi C., Analia M., Nuria F.S., 2007. Health Care-Associated Pneumonia Requiring Hospital Admission. *Am Med Association*, **167**:1393-1399.

- Jung JY, Park MS, Kim YS, Park BH, Kim SK, Chang J, et al., 2011. Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital. *BMC Infect Dis*, **11**:61-71.
- Kang J.S., dan Lee M.H., 2009. Overview of Therapeutic Drug Monitoring. *The Korean J of Int Med*, **24**:1.
- Kollef M.H., Shorr A., Tabak Y.P., Gupta V., Liu L.Z., 2005. Epidemiology and outcomes of health-care associated pneumonia: results from a large US database of culture-positive pneumonia. *Chest*, **128**: 3854-3862.
- Kollef MH., 2008. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. *Clin Infect Dis*. **47**:S3-S13.
- Lee H.L and Kim Y.H., 2012. Comparisson of clinical characteristics between healthcare-associated pneumonia and community-acquired pneumonia in patients admitted to secondary hospitals. *Braz J Infect Dis*, **16**:321-328.
- Leekha, S., Terrell, C.L., dan Edson, R.S., 2011. General Principles of Antimicrobial Therapy. *Mayo Clinic Proceedings*, **86**: 156–167.
- Lescure FX, Locher G, and Eveillard M, 2006. community-acquired infection with healthcare-associated methicillin-resistant *Staphylococcus aureus*: the role of home nursing care. *Infect Control Hosp Epidemiol*, **27**:1213-1218.
- Lexicomp, 2015. *Drug Information Handbook: A Comprehensive Resource for All Clinicians and Healthcare Professionals*. Lexi-Comp.
- Marin H. K., Andrew S., Ying P. T., Larry Z.L., and Johannes R.S., 2005. Epidemiology and Outcomes of Health-care–Associated Pneumonia : Results From a Large US Database of Culture-Positive Pneumonia. *CHEST*, **128** : 3854-3862.
- Menkes RI, 2011. Permenkes Nomor 2406/MENKES/PER/XII/2011 Tentang Pedoman Umum Penggunaan Antibiotik.
- Menkes RI, 2015. Permenkes Nomor 8 Tahun 2015 Tentang Program Pengendalian Resistensi Antimikroba Di Rumah Sakit.
- McKinnon P.S., Paladino J.A., and Schentag J.J., 2008. Evaluation of area under the inhibitory curve (AUC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. *Int J Antimicroba Agents*, **31**:345-51.

- McKinnon P.S., and Davis S.L., 2004. Pharmacokinetic and Pharmacodynamic Issues in the treatment of Bacterial Infectious Disease. *Eur J Clin Microbial Infect Dis*, **23**:271-288.
- Micek ST., Kollef KE., Reichley RM., Roubinian N., and Kollef MH., 2007. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. *Antimicrob Agents Chemotherapy*, **51**:3568-3573.
- Misnadiarly, 2008. *Penyakit Infeksi Saluran Napas Pneumonia Pada Anak, Orang Dewasa, Usia Lanjut, Pneumonia Atipik & Pneumonia Atypik Mycobacterium*, 1st ed. Pustaka Obor Populer, Jakarta.
- Mylotte JM., 2012. Nursing home-acquired pneumonia. *Clin Inf Dis*, **35**:1205-1211.
- Olofsson S.K., Marcusson L.L., and Stromback A., 2007. Dose-related selection of fluoroquinolone resistant *Escherichia coli*. *J Antimicrob Chemother*, **60**:795-801.
- Park HK, Song JU, and Um SW., 2010. Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital. *Respir Med*, **104**:1729–1735.
- Paterson, D.L. dan Bonomo, R.A., 2005. Extended-Spectrum  $\beta$ -Lactamases: a Clinical Update. *Clinical Microbiology Reviews*, **18**: 657–686.
- Perhimpunan Dokter Paru, 2003. Pneumonia Komuniti. *Pedoman diagnosis & Penatalaksanaan di Indonesia*. Jakarta: Perhimpunan Dokter Paru Indonesia Prahasto, I.D., Kristin, E., dan Mustofa., 1995. *Penggunaan Antibiotika Rasional*. Laboratorium Farmakologi Fakultas Kedokteran Universitas Gadjah Mada, Yogyakarta.
- Price, S.A. dan Wilson, L.M., 2006. *Pathophysiologi : Clinical Concept of Diseases Processes*, 6th ed. ECG, Jakarta.
- Restinia, M., Lucida, H., and Gillani, S.W., 2010. Longitudinal clinical evaluation of antibiotic use among patients with infecton. *Int J of Pharmacy & Life Sciences*, **3**: 1935–1945.
- Roberts J.A, Kruger P and Paterson DL., 2008. Antibiotic resistance—what's dosing got to dowith it?. *Crit Care Med*, **36**:2433-2440.
- Ruskanen, O., Lahti, E., Jennings, L.C., and Murdoch, D.R., 2014."Viral pneumonia". *Lancet*, **377**:1264-75.

- Russell T.A and Christopher R.F., 2011. Health Care-Associated Pneumonia : An Evidence-based Review. *The American J of Med*, **124**:688-697.
- Scott T.M, Richard M., and Marin H.K., 2011. Health Care-Associated Pneumonia (HCAP) Empiris Antibiotics Targeting Methicillin-Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa Predict Optimal Outcome. *Medicine*, **90**:390-395.
- Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, *et al.*, 2009. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. *Chest*, **135**:633-640.
- Seymann G.B., 2008. Treatment must cover more virulent pathogen, Health care-associated pneumonia: Meeting the clinical challenges. *The J of Resp Di*, **29**:208-213.
- Seymann G.B., Di Francesco L., Sharpe B., Rohde J., Fedullo P., Schneir A., *et al.*, 2009. The HCAP gap:differences between self-reported practice patterns and published guidelines for health care-associated pneumonia. *Clin Infect Dis*, **49**:1868-1874.
- Shorr AF, Zilberberg MD, Micek ST, and Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. *Arch Intern Med*. 2008;**168**: 2205-2210.
- Siregar, C.J., 2005. *Farmasi Klinik Teori Dan Penerapan*. Penerbit Buku Kedokteran EGP, Jakarta.
- Utterback B.G., and Maki D., 2003. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. *Crit Care Med*, **31**:2291-2301.
- Vicas A, Strom J, Stanley K, and D'Agata EM., 2008. Multidrug-resistant Gram-negative bacteria among patients who require chronic hemodialysis. *Clin J Am Soc Nephrol*, **3**:752-8.
- Winter, M., 1994. *Basic Clinical Farmakokinetiks*, 3rd ed. Vancouver.
- Wells, B.G., 2009. *Pharmacotherapy Handbook*. McGraw-Hill Medical Pub. Division, New York.
- Yuichiro S., Shinji S., and Eiichi M., 2009. Healthcare-Associated Pneumonia Among Hospitalized Patients in a Japanese Community Hospital. *Chest*, **135**:633-640.

Zapantis, A., Lacy, M.K., Horvat, R.T., Grauer, D., Barnes, B.J., O'Neal, B., *et al.*, 2005. Nationwide Antibigram Analysis Using NCCLS M39-A Guidelines. *Journal of Clin Micro*, **43**: 2629–2634.

Zilberberg M.D., Shorr A.F., Micek S.T., Mody S.H., and Kollef M.H., 2008. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single center experience. *Chest*, **134**:963–968.